Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 8/20 | 0.38 |
| ▸ | IGF1R | P08069 | 6/20 | 0.38 |
| ▸ | BTK | Q06187 | 2/20 | 0.36 |
| ▸ | TXK | P42681 | 1/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.34 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.34 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22696565 | 0.95 | TNK2 (0.40) | TNK2IGF1RBTKTXKFGFR1 | |
| SCHEMBL25557512 | 0.88 | TNK2 (0.38) | TNK2IGF1RBTKTXKFGFR1 | |
| SCHEMBL25557496 | 0.86 | RIPK1 (0.37) | TNK2IGF1RFGFR1FGFR3 | |
| SCHEMBL22696567 | 0.85 | TNK2 (0.40) | TNK2IGF1RBTKTXKFGFR1 | |
| SCHEMBL22696342 | 0.81 | FGFR1 (0.51) | TNK2IGF1RTXKFGFR1FGFR2 | |
| SCHEMBL22696560 | 0.81 | TNK2 (0.37) | TNK2IGF1RFGFR1FGFR3 | |
| SCHEMBL25557491 | 0.80 | FGFR1 (0.47) | TNK2IGF1RTXKFGFR1FGFR2 | |
| SCHEMBL25557493 | 0.76 | RIPK1 (0.37) | TNK2IGF1RFGFR1FGFR3 | |
| SCHEMBL25557510 | 0.73 | RIPK1 (0.35) | TNK2IGF1RFGFR1FGFR3FGFR4 | |
| SCHEMBL22696561 | 0.71 | TNK2 (0.37) | TNK2IGF1RFGFR1FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | KINNATE BIOPHARMA INC. | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174535-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | FGFR1, FGFR2, FGFR3 | TNK2 69/4885IGF1R 60/4885BTK 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.